Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Secuencia:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas No. : 159519-65-0
Fórmula molecular : C204H301N51O64
Peso molecular : 4492
Pureza (HPLC) : 98.0%mín..
Apariencia : White to off-white amorphous solid
Impureza única (HPLC) : 0.5%máximo
Composición de aminoácidos : ±10% del teórico
Contenido de péptidos (NORTE%) : ≥80,0%
Contenido de agua (Karl Fischer) : ≤8,0%
TrifluoroAcetate Content(HPIC) : ≤12,0%
EM (ESI) : Coherente
Mass Balance : 95.0~105,0%
Calificación : Grado farmacéutico
Almacenamiento: Closed, below 2 ~ 8℃ preservation
Uso : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (POSADA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
